Editas MedicineEDIT
Recorded

Editas Medicine 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration19 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Debjit ChattopadhyayAnalyst

Good afternoon, and thank you for joining Guggenheim at our 3rd Annual Healthcare Innovations Conference. I am Debjit, one of the therapeutic analysts, and my privilege to welcome Gilmore O'Neill, President and CEO of Editas, and Amy Parison, Chief Financial Officer. Thank you both for making time for us.

Gilmore O’NeillPresident and CEO

It's great to be here.

Debjit ChattopadhyayAnalyst

Thanks for having us. Obviously, the Editas story has evolved over the last couple of years.

Debjit ChattopadhyayAnalyst

Gilmore, why don't you just give us a rundown where you are currently, and then we can Yeah dial in.

Gilmore O’NeillPresident and CEO

Happy to. We are really at the point where we have driven or really close to complete. We have completed the evolution of Editas, where we are an entirely focused in vivo CRISPR editing company. Our lead asset, which we are on track to have patients dosed this year, really epitomizes our strategy, which is one of using the unique capabilities of CRISPR to create non-coding edits that functionally upregulate disease-mitigating proteins. In this case, EDIT-401, our lead asset, replicates a naturally occurring human genetic variant by editing the three' UTR of the LDLR gene, resulting in a significant upregulation, a direct increase in upregulation of that, which is associated with, in our non-human primates, a 90% reduction in LDL cholesterol, along with significant and comparable reductions in Lp(a) and ApoB.

Gilmore O’NeillPresident and CEO

Just at AHA, the American Heart Association, two days ago, we presented an update on the data showing that those effects now are durable out to 10 months in our non-human primates.

Debjit ChattopadhyayAnalyst

Got it. There is plenty to unpack from the AHA, but we will get to that later. Could you help us understand, at least given the non-human primate data that we have seen from the classical PCSK9 editing approaches versus the one that you are pursuing, why does increasing the LDL receptor give you such a deeper LDLC knockdown?

Gilmore O’NeillPresident and CEO

Well, in all cases, they are trying to increase the LDL receptor. We believe that the reason we are able to do this with this effect size in the non-human primate, and hopefully humans, is because we are directly increasing the synthesis of the LDL receptor, whereas the PCSK9 inhibition approach is really trying to inhibit the degradation or recycling. While they are actually targeting recycling of the LDL receptor, we are directly going to the core of the issue, which is increasing synthesis of the LDL receptor.

Debjit ChattopadhyayAnalyst

Got it. Let's talk about the HORIZON study and implications for EDIT-401 development program. The phase I/II study is currently underway.

Debjit ChattopadhyayAnalyst

Yes. Right? Given the learnings from the HORIZON study, is there a specific subset of patients that you would enroll, given you could lower Lp(a) and LDL-C?

Debjit ChattopadhyayAnalyst

There was a signal in the that small subset of patients who had very high LDL-C.

Gilmore O’NeillPresident and CEO

Yes. We've looked at the Lp(a) as what I would call is almost like a no-cost or zero-cost upside. The core central part of our thesis is the LDL-C reduction. There are a couple of takeaways from the HORIZON study. You quite rightly point out the importance of enrolling high-risk patients, and in many ways, it validates our current approach in our phase I/II to target very high-risk patients. In this case, right now, we're leading with HeFH, but we can expand to non-HeFH patients, but very high-risk patients with atherosclerotic cardiovascular disease who cannot get to target LDL cholesterol with the current standard of care. I have to say, one of the takeaways from HORIZON was it absolutely validated the critical need of getting LDL cholesterol low in these patients.

Gilmore O’NeillPresident and CEO

You will recall that the event rate in the HORIZON study was actually very low and is probably driven by the LDL cholesterol. But to your point about the subset of patients, those high-risk patients, those are patients who are already enrolling. We are really focused on the LDL as the selection criteria, and I think at later points, we would look at the Lp effect.

Debjit ChattopadhyayAnalyst

Got it. From the dose that you plan to take in the clinic or where you would like to see therapeutic activity- help us understand the window of opportunity you have, because in the end, this is all LNP-mediated.

Gilmore O’NeillPresident and CEO

Yes. From the point of view of the effect size, obviously, we're going into a Part 1 of our phase I/II study is a serial cohort dose escalation study. We're starting at a non-therapeutic dose for obvious reasons, just to ensure and maximize subject safety, and then we will escalate to higher dose and get to what we think is our target efficacious dose in subsequent cohorts. Apropos the LNP delivery, I think, and I hope that I'm getting to answer the right question, in the context of HeFH, obviously, patients don't have or have an abnormal, one copy of the LDLR gene is abnormal, and therefore could impair naked LNP uptake.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day